Biogen Jefferies Global Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
conference. I am Andrew Tsai, Senior Biotech Analyst at Jefferies, and it is my pleasure to have Alisha Alaimo joining me today from Biogen, President, Head of North America. Welcome, Alisha. Thank you. Maybe to get started, Alisha, I have viewed Biogen as a $10 billion base business that is now growing thanks to the Apellis transaction.
You have a whole suite of pipeline readouts coming up. As investors think about the growth profile of Biogen longer term, what products do you think could surprise to the upside?
Thank you for the question. Also, thank you for everyone that showed up in the room today. There is nothing like talking to an empty room, so I love seeing some good-looking faces, and for all of you that have dialed in, and thank you for inviting me here today. You are exactly right. Well, first of all, Biogen, I believe, is really at their turnaround point. If you think we have been in existence for almost 50 years, about four years ago when Chris Viehbacher started is really when the turnaround story started. For any of you that dialed into any of the calls, we really put a lot of effort in reducing our cost base, right, reallocating our capital. We also cleaned up a lot of the operations that we had. We reprioritized our pipeline, which, by the way, that is why these next couple readouts become very important.
That work started four years ago. On top of where are we going to put the money if we have to do any deals? In parallel to that, we've been in a very special situation where we've been doing. We had seven launches in seven years. Not many companies can say that of our size. Because our size is really, I think, the sweet spot in the industry, you get very close and can do things very quickly with agility. When you see the market changing beneath our feet, which we've seen a lot of in the last couple years, especially with a lot of the government regulations and changes that are coming out, the question really becomes, can your teams move at the same speed that the market is moving? Because the market is now beating a lot of the organizations that you see.
As we look towards our readouts, which are very pivotal readouts for us, and we look at the future of the organization, commercial capabilities now in biopharma become so important. Because as you see drug launches, gone are the days that you just need a field force, you just need some access, and all of a sudden you hit $1 billion. You have to move with that speed. Because of those capabilities, you will see there are now proof points for our future products. If you look at MS, which was the melting iceberg that Chris so famously called it, you can see how resilient it's become. Those capabilities we built with maintaining that business is what is going to make lupus and felzartamab and AMR and multiple indications very, very successful.
In addition to that, when you look at the products in our portfolio, or if you look at the most recent acquisition with Apellis, I think everyone thought of SYFOVRE as a product that would constantly be declining. If you look at quarter three, I think it surprised a lot of people. That is due to commercial capabilities that we were able to put in place very quickly. As we look forward to the company and as we look at the turnaround and getting back to revenue growth, which we, of course, want to grow next year, if Biogen grows next year, that will be the first time since 2019 that we've grown. A couple of the products to keep, I believe, your eyes on. First of all, LEQEMBI. I know in the beginning everyone wanted LEQEMBI to take off way faster than what it did.
Of course, we did as well. But now that you see how difficult that market is, we're now at a point where you can expect quarter-over-quarter growth. With the launch of IQLIK, we're seeing very interesting early signals where you have physicians who have never written LEQEMBI or KISUNLA before writing IQLIK. You're also seeing switches from KISUNLA to IQLIK. That is already laying the path that subq becomes a very important option for this patient population. I think LEQEMBI is one to keep an eye on. Another one, which not a lot of people ask about, but you'll probably go back and look at the numbers, is ZURZUVAE for postpartum depression. If you look at the growth that we've had every single year, it's been quite impressive. Very large market, very large runway. I don't spend a lot of money on ZURZUVAE.
However, this market has lots of tailwinds, especially with mothers. What you are going to see is this will also be a nice growth year-over-year for several years to come. If you look at SYFOVRE and EMPAVELI in the most recent deal, you will see that EMPAVELI is growing at a nice clip in an ultra-rare disease. In the quarter, one of the things that we did uncover once they were underneath our umbrella, C3G and IC-MPGN, the team has done a very good job of especially getting pediatrics and severe patients on product. Where we were losing, though, was in PNH, and it is my understanding PNH was not actually discussed quite a bit. Literally within four weeks, we were able to identify the issue and baseline that.
We stopped the bleeding, and we are already back to growth on PNH, which tells you how highly sensitive it is. Also with precision, if you go to the right physicians, you can actually turn it around. I think EMPAVELI is another one. Last but not least, of course, is SYFOVRE. There is actually a very good runway there. We were very conservative with how we modeled this when we did the deal, but I think after you have seen a couple of quarters of growth, not just in volume, but also some of the things that we put in place, which are the Biogen rules on how you deal with free patients, how you ensure there is coverage, understanding how you compete in the market, you are starting to see that take place.
I think we have identified a couple other issues in geographic atrophy that we are going to be able to tackle quite quickly and over the next years, and I think you can also expect SYFOVRE to grow as well, which I think was probably not on anyone's dance card.
Very clear. Thanks. Very helpful. Maybe starting with LEQEMBI, just a couple questions. Now that you have the subq full at-home use, just feels like the world is your oyster a little bit here. What is the bottleneck left after? Let us just assume you did get payer access January 1st. What else is there in terms of volume?
I think subq, the interesting thing that we've noticed, it's really changed the convenience conversation. When you look at the market and people started looking at LEQEMBI versus KISUNLA, the only reason for any of you who even go out and speak to physicians or talk to them, they will say, "We like the once-monthly dosing, and we like to know that we can potentially stop it if we think the plaques are cleared." We, of course, believe that Alzheimer's is a chronic disease. It is something that you do need ongoing treatment for. Introducing subq, which is a stay-at-home option for these patients, has changed that convenience conversation.
The fascinating thing that you see with IQLIK is that when we first introduced maintenance dosing with subq, the questions that we would have is, "Well, why don't I see subq flying off the shelf with maintenance?" In this therapeutic area, because the patients are older and many of the patients don't have a lot of activities outside of their home, going for an IV infusion gives them a sense of community. They plan their appointments with the people that they've met while they've been there, and they get on a cadence where it becomes a social gathering for them. For that cohort of patients in the very beginning when they wanted subq, we learned they wanted it to go on cruises.
Cruises apparently a very big thing in this age group, and man, do they love taking subq on their cruise and not having to come in for an IV. Now you go to IQLIK. For initiation, we are seeing everything happen across the board. We see LEQEMBI IV patients transitioning to IQLIK. We see KISUNLA IV transitioning. We see, as I said earlier, people who've never written the products start IQLIK. We're also seeing the LEQEMBI IV transitions as well, but we also see that they end up going back sometimes. The great thing is optionality in the younger patient cohort becomes increasingly important. If you think about the potential readout for the trial, like AHEAD 3-45 in the pre-symptomatic patient, those will be younger patients who are still working. They want to work for as long as they can.
Subq becomes also a great option for them.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
